This RFI is issued solely for information and planning purposes and does not constitute a solicitation. Nonetheless, submitters should properly mark their responses if the information is confidential. Furthermore, those who respond to this RFI should not anticipate feedback with regards to its submission other than acknowledgment of receipt, should the submitter request an acknowledgement. In accordance with FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. All submissions become the property of the Federal Government and will not be returned. Responders are solely responsible for all expense associated with responding to this RFI.

The United States Department of Homeland Security (DHS), Office of Health Affairs (OHA), requires antiviral medications for a highly pathogenic outbreak that could lead to a pandemic. DHS was appropriated funding in accordance with PL 109-148 for the preparation, planning and mitigation of a pandemic influenza. DHS has been closely monitoring the effectiveness of pharmaceutical interventions as a part of its overall pandemic preparedness plan. Additionally, DHS has been working closely with the Department of Health and Human Services (HHS) with regards to antivirals, and the pre-positioning of antivirals in the Strategic National Stockpile. DHS OHA has oversight and planning responsibility for all DHS components with regards to the DHS Antiviral Stockpile.

This RFI specifically seeks information for qualified pharmaceutical manufacturers with drug manufacturing expertise and experience capabilities with the ability to provide antiviral medication to support the United States of America and the continuity of government. The antivirals must be approved by the Food and Drug Administration and demonstrated by the Centers for Disease Control to be effective in treating Influenza A, H1N1 Influenza and H5N1 Avian Influenza.

Please see attached RFI for complete details and submission instructions.